Skip to main content
Top
Published in: Clinical Rheumatology 8/2009

01-08-2009 | Original Article

Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up

Authors: K. P. Ng, F. Ramos, S. M. Sultan, D. A. Isenberg

Published in: Clinical Rheumatology | Issue 8/2009

Login to get access

Abstract

This study aims to report the concomitant diseases observed and damage outcome in a cohort of patients with adult idiopathic inflammatory myositis (IIM) during long-term follow-up. All patients with IIM were identified from a single centre (follow-up between 1979 and 2006) and fulfilled at least three of the four Bohan and Peter criteria. Patients with inclusion body myositis, juvenile-onset myositis and overt overlap syndromes were excluded. Medical notes were retrospectively reviewed. Concomitant diseases identified were divided into 12 different organ systems (bone, cardiac, respiratory, gastrointestinal, renal, central nervous, malignancy, infection, endocrine, eyes, dermatological and haematological). Patient damage index was calculated using the Myositis Damage Index tool. Fifty-five patients (31 polymyositis, 24 dermatomyositis) were identified. The most prevalent organ system involved was lung with 40 events per 1,000 patient years follow-up. There was significant steroid-related complications with 17/18 patients with bone involvement having osteopenia/osteoporosis. Sjogren's syndrome (n = 3) was the most frequent concomitant auto-immune disease observed. Patients with a higher number of organ systems involved had a significantly higher damage index (r = 0.48, p = 0.001). White patients showed a significant trend to develop more than three other organ system involvement (p < 0.0001) and myositis-related lung disease (p < 0.0001) compared to other races. There is significant steroid-related morbidity in adult IIM patients under long-term follow-up. The prevalence of another concomitant auto-immune disease unlike patients with lupus or Sjogren's syndrome is low.
Literature
1.
go back to reference Ehrenstein MR, Snaith ML, Isenberg DA (1992) Idiopathic myositis: a rheumatological view. Ann Rheum Dis 51(1):41–44PubMedCrossRef Ehrenstein MR, Snaith ML, Isenberg DA (1992) Idiopathic myositis: a rheumatological view. Ann Rheum Dis 51(1):41–44PubMedCrossRef
2.
go back to reference Sultan SM, Ioannou Y, Moss K, Isenberg DA (2002) Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 41(1):22–26CrossRef Sultan SM, Ioannou Y, Moss K, Isenberg DA (2002) Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 41(1):22–26CrossRef
3.
go back to reference Marie I, Hachulla E, Hatron PY et al (2001) Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol 28(10):2230–2237PubMed Marie I, Hachulla E, Hatron PY et al (2001) Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol 28(10):2230–2237PubMed
4.
go back to reference Ponyi A, Borgulya G, Constantin T, Vancsa A, Gergely L, Danko K (2005) Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford) 44(1):83–88CrossRef Ponyi A, Borgulya G, Constantin T, Vancsa A, Gergely L, Danko K (2005) Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford) 44(1):83–88CrossRef
5.
go back to reference Airio A, Kautiainen H, Hakala M (2006) Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 25(2):234–239PubMedCrossRef Airio A, Kautiainen H, Hakala M (2006) Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 25(2):234–239PubMedCrossRef
6.
go back to reference Torres C, Belmonte R, Carmona L et al (2006) Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 39(3):205–215PubMedCrossRef Torres C, Belmonte R, Carmona L et al (2006) Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 39(3):205–215PubMedCrossRef
7.
go back to reference Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM (1996) Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 14(3):263–274PubMed Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM (1996) Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 14(3):263–274PubMed
8.
go back to reference Tymms KE, Webb J (1985) Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 12(6):1140–1148PubMed Tymms KE, Webb J (1985) Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 12(6):1140–1148PubMed
9.
go back to reference Rios G (2005) Retrospective review of the clinical manifestations and outcomes in Puerto Ricans with idiopathic inflammatory myopathies. J Clin Rheumatol 11(3):153–156PubMedCrossRef Rios G (2005) Retrospective review of the clinical manifestations and outcomes in Puerto Ricans with idiopathic inflammatory myopathies. J Clin Rheumatol 11(3):153–156PubMedCrossRef
10.
go back to reference Uthman I, Vázquez-Abad D, Senécal JL (1996) Distinctive features of idiopathic inflammatory myopathies in French Canadians. Semin Arthritis Rheum 26(1):447–458PubMedCrossRef Uthman I, Vázquez-Abad D, Senécal JL (1996) Distinctive features of idiopathic inflammatory myopathies in French Canadians. Semin Arthritis Rheum 26(1):447–458PubMedCrossRef
11.
go back to reference McDonagh JE, Isenberg DA (2000) Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Ann Rheum Dis 59(3):230–232PubMedCrossRef McDonagh JE, Isenberg DA (2000) Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Ann Rheum Dis 59(3):230–232PubMedCrossRef
12.
go back to reference Chambers SA, Charman SC, Rahman A, Isenberg DA (2007) Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality. Ann Rheum Dis 66(9):1173–1177PubMedCrossRef Chambers SA, Charman SC, Rahman A, Isenberg DA (2007) Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality. Ann Rheum Dis 66(9):1173–1177PubMedCrossRef
13.
go back to reference Lazarus MN, Isenberg DA (2005) Development of additional autoimmune diseases in a population of patients with primary Sjogren's syndrome. Ann Rheum Dis 64(7):1062–1064PubMedCrossRef Lazarus MN, Isenberg DA (2005) Development of additional autoimmune diseases in a population of patients with primary Sjogren's syndrome. Ann Rheum Dis 64(7):1062–1064PubMedCrossRef
14.
go back to reference Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347PubMed Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347PubMed
15.
go back to reference Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407PubMed Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407PubMed
16.
go back to reference Vitali C, Bombardieri S, Moutsopoulos HM et al (1993) Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 36(3):340–347PubMedCrossRef Vitali C, Bombardieri S, Moutsopoulos HM et al (1993) Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 36(3):340–347PubMedCrossRef
17.
go back to reference Clarke AE, Bloch DA, Medsger TA Jr, Oddis CV (1995) A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum 38(9):1218–1224PubMedCrossRef Clarke AE, Bloch DA, Medsger TA Jr, Oddis CV (1995) A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum 38(9):1218–1224PubMedCrossRef
18.
go back to reference Bronner IM, van der Meulen MF, de Visser M et al (2006) Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 65(11):1456–1461PubMedCrossRef Bronner IM, van der Meulen MF, de Visser M et al (2006) Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 65(11):1456–1461PubMedCrossRef
19.
go back to reference Marie I, Hachulla E, Cherin P et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47(6):614–622PubMedCrossRef Marie I, Hachulla E, Cherin P et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47(6):614–622PubMedCrossRef
20.
go back to reference Selva-O'Callaghan A, Labrador-Horrillo M, Munoz-Gall X et al (2005) Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus 14(7):534–542PubMedCrossRef Selva-O'Callaghan A, Labrador-Horrillo M, Munoz-Gall X et al (2005) Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus 14(7):534–542PubMedCrossRef
21.
go back to reference Yaqub S, Moder KG, Lacy MQ (2004) Severe, reversible pulmonary hypertension in a patient with monoclonal gammopathy and features of dermatomyositis. Mayo Clin Proc 79(5):687–689PubMedCrossRef Yaqub S, Moder KG, Lacy MQ (2004) Severe, reversible pulmonary hypertension in a patient with monoclonal gammopathy and features of dermatomyositis. Mayo Clin Proc 79(5):687–689PubMedCrossRef
22.
go back to reference Grateau G, Roux ME, Franck N et al (1993) Pulmonary hypertension in a case of dermatomyositis. J Rheumatol 20(8):1452–1453PubMed Grateau G, Roux ME, Franck N et al (1993) Pulmonary hypertension in a case of dermatomyositis. J Rheumatol 20(8):1452–1453PubMed
23.
go back to reference Kissel JT, Mendell JR, Rammohan KW (1986) Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 314(6):329–334PubMed Kissel JT, Mendell JR, Rammohan KW (1986) Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 314(6):329–334PubMed
24.
go back to reference Wakata N, Kurihara T, Saito E, Kinoshita M (2002) Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 41(11):729–734PubMedCrossRef Wakata N, Kurihara T, Saito E, Kinoshita M (2002) Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 41(11):729–734PubMedCrossRef
25.
go back to reference Hill CL, Zhang Y, Sigurgeirsson B et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357(9250):96–100PubMedCrossRef Hill CL, Zhang Y, Sigurgeirsson B et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357(9250):96–100PubMedCrossRef
26.
go back to reference Sigurgeirsson B, Lindelof B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326(6):363–367PubMedCrossRef Sigurgeirsson B, Lindelof B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326(6):363–367PubMedCrossRef
27.
go back to reference Bernatsky S, Boivin JF, Joseph L et al (2005) An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52(5):1481–1490PubMedCrossRef Bernatsky S, Boivin JF, Joseph L et al (2005) An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52(5):1481–1490PubMedCrossRef
28.
go back to reference Bernatsky S, Clarke AE, Suissa S (2008) Haematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 168(4):378–381PubMedCrossRef Bernatsky S, Clarke AE, Suissa S (2008) Haematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 168(4):378–381PubMedCrossRef
29.
go back to reference Biro E, Szekanecz Z, Czirjak L et al (2006) Association of systemic and thyroid autoimmune diseases. Clin Rheumatol 25(2):240–245PubMedCrossRef Biro E, Szekanecz Z, Czirjak L et al (2006) Association of systemic and thyroid autoimmune diseases. Clin Rheumatol 25(2):240–245PubMedCrossRef
30.
go back to reference Koh ET, Seow A, Ong B, Ratnagopal P, Tjia H, Chng HH (1993) Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 52(12):857–861PubMedCrossRef Koh ET, Seow A, Ong B, Ratnagopal P, Tjia H, Chng HH (1993) Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 52(12):857–861PubMedCrossRef
31.
go back to reference Shamim EA, Miller FW (2000) Familial autoimmunity and the idiopathic inflammatory myopathies. Curr Rheumatol Rep 2(3):201–211PubMedCrossRef Shamim EA, Miller FW (2000) Familial autoimmunity and the idiopathic inflammatory myopathies. Curr Rheumatol Rep 2(3):201–211PubMedCrossRef
32.
go back to reference Marie I, Hachulla E, Cherin P et al (2005) Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 53(2):155–165PubMedCrossRef Marie I, Hachulla E, Cherin P et al (2005) Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 53(2):155–165PubMedCrossRef
33.
go back to reference Viguier M, Fouere S, de la Salmoniere P et al (2003) Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine (Baltimore) 82(2):82–86CrossRef Viguier M, Fouere S, de la Salmoniere P et al (2003) Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine (Baltimore) 82(2):82–86CrossRef
34.
go back to reference Ishida Y, Utikoshi M, Kurosaki M et al (1998) Hepatic veno-occlusive disease in a case of polymyositis associated with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Intern Med 37(8):694–699PubMedCrossRef Ishida Y, Utikoshi M, Kurosaki M et al (1998) Hepatic veno-occlusive disease in a case of polymyositis associated with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Intern Med 37(8):694–699PubMedCrossRef
35.
go back to reference Miller FW, Rider LG, Chung YL et al (2001) International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 40(11):1262–1273CrossRef Miller FW, Rider LG, Chung YL et al (2001) International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 40(11):1262–1273CrossRef
36.
go back to reference Isenberg DA, Allen E, Farewell V et al (2004) International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43(1):49–54CrossRef Isenberg DA, Allen E, Farewell V et al (2004) International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43(1):49–54CrossRef
37.
go back to reference Sultan SM, Allen E, Oddis CV et al (2008) Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum 58(11):3593–3599PubMedCrossRef Sultan SM, Allen E, Oddis CV et al (2008) Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum 58(11):3593–3599PubMedCrossRef
38.
go back to reference Shamim EA, Rider LG, Pandey JP et al (2002) Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 46(7):1885–1893PubMedCrossRef Shamim EA, Rider LG, Pandey JP et al (2002) Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 46(7):1885–1893PubMedCrossRef
39.
go back to reference O'Hanlon TP, Rider LG, Mamyrova G et al (2006) HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum 54(11):3670–3681PubMedCrossRef O'Hanlon TP, Rider LG, Mamyrova G et al (2006) HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum 54(11):3670–3681PubMedCrossRef
Metadata
Title
Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up
Authors
K. P. Ng
F. Ramos
S. M. Sultan
D. A. Isenberg
Publication date
01-08-2009
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 8/2009
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-009-1181-4

Other articles of this Issue 8/2009

Clinical Rheumatology 8/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine